Relay Therapeutics (NASDAQ:RLAY) & ReNeuron Group (OTCMKTS:RNUGF) Head to Head Comparison

ReNeuron Group (OTCMKTS:RNUGF) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for ReNeuron Group and Relay Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Relay Therapeutics	1	0	4	1	2.83

Relay Therapeutics has a consensus target price of $16.80, suggesting a potential upside of 62.16%. Given Relay Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than ReNeuron Group.

Profitability

This table compares ReNeuron Group and Relay Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Relay Therapeutics	N/A	-43.17%	-39.22%

Risk and Volatility

ReNeuron Group has a beta of -0.6, meaning that its stock price is 160% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

97.0% of Relay Therapeutics shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ReNeuron Group and Relay Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	N/A	-$6.52 million	N/A	N/A
Relay Therapeutics	$15.35 million	120.63	-$276.48 million	($1.62)	-6.40

ReNeuron Group has higher earnings, but lower revenue than Relay Therapeutics.

Summary

Relay Therapeutics beats ReNeuron Group on 8 of the 11 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Relay Therapeutics

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.